艾司西酞普兰快速剂量滴定治疗广泛性焦虑障碍的对照研究

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (11): 1263-1267.

艾司西酞普兰快速剂量滴定治疗广泛性焦虑障碍的对照研究

沈仲夏^1,2,沈鑫华²,蔡敏²,方瑜²,林敏²,杨剑虹²,许毅³

¹ 浙江大学医学院,杭州 310058,浙江; ² 湖州市第三人民医院, 湖州 313000, 浙江; ³ 浙江大学附属第一医院精神科,杭州 310009,浙江

收稿日期:2013-12-05 修回日期:2014-09-09 出版日期:2014-11-26 发布日期:2014-12-09
通讯作者: 许毅，博导，主要从事心身医学的研究。Tel:13805746579 E-mail:xuyizju@163.com
作者简介:沈仲夏，男，在读硕士，主要从事心身医学的临床治疗及发病机制的研究。Tel:13867291596 E-mail:snowszx@sina.com
基金资助:
浙江省公益技术运用研究项目（2012C33006）

Control research on fast up⁃titration of escitalopram in the treatment of generalized anxiety disorder

SHEN Zhong⁃xia^1,2, SHEN Xing⁃hua²,CAI Min²,FANG Yu²,LIN Min², YANG Jian⁃hong², XU Yi³

¹ Zhejiang University School of Medicine,Hangzhou 310058 Zhejiang,China;
² The Third People's Hospital of Huzhou City, Huzhou 313000,Zhejiang, China;
³ Department of psychiatric, the First Affiliated Hospitol of Zhejiang University School of Medicine, Hangzhou 310009,Zhejiang, China

Received:2013-12-05 Revised:2014-09-09 Online:2014-11-26 Published:2014-12-09

摘要/Abstract

摘要： 目的: 观察艾司西酞普兰快速滴定能否加快起效速度及提高8周疗效。方法: 将78例符合ICD?10广泛性焦虑障碍的患者随机分成艾司西酞普兰快速滴定组(1周内艾司西酞普兰加量至 20 mg/d)(n=36)和艾司西酞普兰常规滴定组(2周内艾司西酞普兰加量至 20 mg/d)(n=42),治疗持续8周,用广泛性焦虑量表?7(GAD?7)评定患者焦虑症状及疗效,同时用TESS和实验室检查评估治疗安全性。结果: 治疗1、2、4、8周末快速滴定组GAD?7减分率均大于常规滴定组。第1、2、4、8周末艾司西酞普兰快速滴定组的治愈率分别为 11.1%、27.8%、50.0%、72.2%,常规滴定组治愈率分别为 2.4%、11.9%、23.8%、50.0%。第1、2、4、8周末艾司西酞普兰快速滴定组的有效率分别为 33.3%、50.0%、63.9%、88.9%,常规滴定组有效率分别为 11.9%、26.2%、42.9%、66.7%,快速滴定组疗效优于常规滴定组(P<0.05)。两组不良反应差异无统计学意义。结论:艾司西酞普兰快速滴定治疗广泛性焦虑障碍可以加快起效速度,提高8周整体疗效,同时不会显著增加药物不良反应。

关键词: 艾司西酞普兰, 快速滴定, 广泛性焦虑障碍, 广泛性焦虑量表?7

Abstract: AIM: To explore wether fast up?titration of escitalopram can make patients with generalized anxiety disorder (GAD) response quicker and elevate the efficacy by the end of the 8th week. METHODS: 78 patients who meet ICD?10 criteria for GAD were divided into escitalopram fast up?titration group (n=36) and normal up?titration group(n=42) randomly. The trial lasted 8 weeks. The anxiety status and efficacy was evaluated with GAD?7(Generalized Anxiety Disorder Scale?7) on the baseline, 1st, 2th, 4th, 8th weekend respectively and the safety was evaluated by TESS and laboratory examination. RESULTS: The GAD?7 scores in fast up?titration group declined quicker than that in normal up?titration group by the end of 1st, 2th, 4th,8th week(P<0.05) respectively. The remission rate of fast up?titration group were 11.1%,27.8%,50.0%,72.2%, and response rate is 33.3%,50.0%,63.9%,88.9%,while the remission rate of normal up?titration group was 2.4%,11.9%,23.8%,50.0%, and response rate was 11.9%,26.2%,42.9%,66.7% at the end of 1st, 2th, 4th,8th weekend .The whole efficacy of fast up?titration group was better than normal up?titration group (P<0.05) .The side effects of both groups had no significant difference(P>0.05).CONCLUSION: Fast up?titration of escitalopram demonstrated to be more effective in the treatment of GAD, and response faster, while the safety is similar.

Key words: escitalopram, fast up?titration, generalized anxiety disorder, GAD?7

中图分类号:

R749.7⁺²

沈仲夏,沈鑫华,蔡敏,方瑜,林敏,杨剑虹,许毅. 艾司西酞普兰快速剂量滴定治疗广泛性焦虑障碍的对照研究[J]. 中国临床药理学与治疗学, 2014, 19(11): 1263-1267.

SHEN Zhong⁃xia, SHEN Xing⁃hua,CAI Min,FANG Yu,LIN Min, YANG Jian⁃hong, XU Yi. Control research on fast up⁃titration of escitalopram in the treatment of generalized anxiety disorder[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1263-1267.

参考文献 16

[1]	Kessler RC, Berglund P, Demler O, et al.Lifetime prevalence and age?of?onset distributions of DSM?IV disorders in the National Comorbidity Survey Replication[J]. Arch Gen Psychiatry,2005,62(6): 593?602.
[2]	Phillips MR,Zhang J,Shi Q,et al.Prevalence,treatment,and associated disability of mental disorders in four provinces in China during 2001-05:an epidemiological survey[J]. Lancet,2009,373(9680): 2041?2053.
[3]	Hoffman DL,Dukes EM,Wittchen HU.Human and economic burden of generalized anxiety disorder[J]. Depress Anxiety,2008,25 (1):72?90.
[4]	Davidson JR, Zhang W, Connor KM,et al. A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD) [J] . J Psychopharmacol, 2010,24(1):3?26.
[5]	Stahl SM. Stahl's essential psychopharmacology neuroscientic basis and practical application.3rd edt [M]//New York: Cambridge University Press, 2008:767.
[6]	Bereza BG,Machado M,Ravindran AV,et al.Evidence?based review of clinical outcomes of guideline?recommended pharmacotherapies for generalized anxiety disorder[J]. Can J Psychiatry,2012,57 (8):470?478.
[7]	Davideson JR, Bose A, Kozotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: Double?blind, placebo controlled, flexible?dose study[J].Depress Anxiety, 2004,19(4):234?240.
[8]	沈仲夏,关铁峰,沈鑫华,等.艾司西酞普兰与文拉法辛缓释剂治疗广泛性焦虑障碍的对照研究[J].中国临床药理学与治疗学,2012,17(10):1167?1170.
[9]	何筱衍,李春波,钱洁,等.广泛性焦虑量表在综合性医院的信度和效度研究[J].上海精神医学, 2010,22(4):200?203.
[10]	Spitzer RL, Kroenke K, Williams JBW, et al A brief measure for assessing generalized anxiety disorder: the GAD?7[J]. Arch Intern Med, 2006, 166: 1092?1097.
[11]	吴文源.焦虑障碍防治指南[M].北京:人民卫生出版社,2010:25.
[12]	Bose A, Korotzer A, Gommoll C, et al. Randomized placebo?controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder[J]. Depress Anxiety, 2008,25(10):854?861.
[13]	司天梅,黄继忠,于欣.Stahl精神药理学精要(神经科学基础与临床应用)(3版)[M]//北京:北京大学医学出版社,2011:454?455.
[14]	司天梅,黄继忠,于欣.Stahl精神药理学精要(神经科学基础与临床应用)(3版)[M]//北京:北京大学医学出版社,2011:467?468.
[15]	Goodman WK, Bose A, Wang Q, et al. Treatment of generalized anxiety disorder with escitalopram: Pooled results from double?blind, placebo?controlled trials[J]. J Affect Disord, 2005,87(2/3):161?167.
[16]	Montgomery SA,Sheehan DV,Meoni P,et al.Characterization of the longitudinal course of improvement in generalized anxiety disorder during long?term treatment with venlafaxine XR[J].J Psychiatr Res,2002,36(4): 209?217.